Molecular aspects of MERS-CoV

“…NTZ exhibits antiviral activity against MERS-CoV and other coronaviruses by inhibiting the expression of the viral N protein, 94 , 95 and inhibits the SARS-CoV-2 at a low-micromolar concentration. 23 One small prospective non-controlled study that assessed NTZ treatment of in and outpatients with COVID-19 was performed.…”

“…(10) Assim, embora o vírus tenha se tornado conhecido atualmente, essa família já foi responsável por grandes epidemias, como pelo SARS-CoV em 2002 ocorrida na China e Taipei; e MERS-CoV que chegou afetar, aproximadamente, 24 países em 2012. (7) Brazilian Journal of Health Review, Curitiba, v.4, n.2, p. 5952-5960 ,mar./apr. 2021 Assim, embora o SARS-CoV-2 seja intitulado como o "novo coronavírus", sua estrutura genética carrega uma sequência genética com, aproximadamente 79% de semelhança em relação ao SARS-CoV (9) .…”

“…VLPs have been extensively used as prophylactic or therapeutic vaccine platforms for a wide range of diseases. In this section, we aim to discuss some examples of the preclinical application of VLPs as a vaccine platform for successful induction of antibodies and/or T-cell responses in both prophylactic and therapeutic regimens in the following diseases: infectious diseases (examples discussed: Middle East respiratory syndrome, coronavirus disease 2019 (COVID- 19), influenza, malaria and acquired immunodeficiency disease (AIDS), inflammation, allergy, pain, neurodegenerative diseases (Alzheimer's and Parkinson's disease) and cancer).…”

“…Accordingly, the receptor is used as the principle targeting agent against the virus in vaccine development. Preclinical studies were performed to develop vaccines against MERS-CoV using different platforms, including VLPs [19,20].…”

“…NTZ exhibits antiviral activity against MERS-CoV and other coronaviruses by inhibiting the expression of the viral N protein, 94 , 95 and inhibits the SARS-CoV-2 at a low-micromolar concentration. 23 One small prospective non-controlled study that assessed NTZ treatment of in and outpatients with COVID-19 was performed.…”

“…(10) Assim, embora o vírus tenha se tornado conhecido atualmente, essa família já foi responsável por grandes epidemias, como pelo SARS-CoV em 2002 ocorrida na China e Taipei; e MERS-CoV que chegou afetar, aproximadamente, 24 países em 2012. (7) Brazilian Journal of Health Review, Curitiba, v.4, n.2, p. 5952-5960 ,mar./apr. 2021 Assim, embora o SARS-CoV-2 seja intitulado como o "novo coronavírus", sua estrutura genética carrega uma sequência genética com, aproximadamente 79% de semelhança em relação ao SARS-CoV (9) .…”

“…VLPs have been extensively used as prophylactic or therapeutic vaccine platforms for a wide range of diseases. In this section, we aim to discuss some examples of the preclinical application of VLPs as a vaccine platform for successful induction of antibodies and/or T-cell responses in both prophylactic and therapeutic regimens in the following diseases: infectious diseases (examples discussed: Middle East respiratory syndrome, coronavirus disease 2019 (COVID- 19), influenza, malaria and acquired immunodeficiency disease (AIDS), inflammation, allergy, pain, neurodegenerative diseases (Alzheimer's and Parkinson's disease) and cancer).…”

“…Accordingly, the receptor is used as the principle targeting agent against the virus in vaccine development. Preclinical studies were performed to develop vaccines against MERS-CoV using different platforms, including VLPs [19,20].…”

“…NTZ exhibits antiviral activity against MERS-CoV and other coronaviruses by inhibiting the expression of the viral N protein, 94 , 95 and inhibits the SARS-CoV-2 at a low-micromolar concentration. 23 One small prospective non-controlled study that assessed NTZ treatment of in and outpatients with COVID-19 was performed.…”

“…(10) Assim, embora o vírus tenha se tornado conhecido atualmente, essa família já foi responsável por grandes epidemias, como pelo SARS-CoV em 2002 ocorrida na China e Taipei; e MERS-CoV que chegou afetar, aproximadamente, 24 países em 2012. (7) Brazilian Journal of Health Review, Curitiba, v.4, n.2, p. 5952-5960 ,mar./apr. 2021 Assim, embora o SARS-CoV-2 seja intitulado como o "novo coronavírus", sua estrutura genética carrega uma sequência genética com, aproximadamente 79% de semelhança em relação ao SARS-CoV (9) .…”

“…VLPs have been extensively used as prophylactic or therapeutic vaccine platforms for a wide range of diseases. In this section, we aim to discuss some examples of the preclinical application of VLPs as a vaccine platform for successful induction of antibodies and/or T-cell responses in both prophylactic and therapeutic regimens in the following diseases: infectious diseases (examples discussed: Middle East respiratory syndrome, coronavirus disease 2019 (COVID- 19), influenza, malaria and acquired immunodeficiency disease (AIDS), inflammation, allergy, pain, neurodegenerative diseases (Alzheimer's and Parkinson's disease) and cancer).…”

“…Accordingly, the receptor is used as the principle targeting agent against the virus in vaccine development. Preclinical studies were performed to develop vaccines against MERS-CoV using different platforms, including VLPs [19,20].…”